ONCOassist

14/01/2026

🚨Latest Update!

🧬 ImmunityBio reported positive results showing ANKTIVA® (nogapendekin alfa inbakicept) as a lymphocyte-stimulating agent when combined with checkpoint inhibitors in non-small cell lung cancer (NSCLC).

📈 Across two trials, ANKTIVA® + checkpoint inhibitor (CPI) significantly restored lymphocyte counts and was associated with improved overall survival, with a phase 3 confirmatory study ongoing.

🔗 Read more: bit.ly/ONCOnews14J-04

14/01/2026

🚨New Trial Update!

🫁 NRG Oncology/Alliance LU005 evaluated chemoradiation with or without atezolizumab in patients with limited-stage small cell lung cancer (LS-SCLC).

📊 Adding atezolizumab did not improve overall survival (OS), progression-free survival (PFS), and distant metastasis–free survival (DMFS) vs chemoradiation alone, with no unexpected safety signals observed.

🔗 Read more: bit.ly/ONCOnews14J-03

14/01/2026

🚨Latest Trial Update!

🫁 The BR.31 trial evaluated adjuvant durvalumab in patients with completely resected early-stage non-small cell lung cancer (NSCLC).

📉 After 5 years of follow-up, durvalumab showed no disease-free survival (DFS) benefit over placebo in EGFR–/ALK– NSCLC and had more grade 3 - 4 side effects.

🔗 Read more: bit.ly/ONCOnews14J-02

14/01/2026

🚨Latest Phase III Trial Results!

🫁 Adjuvant Aumolertinib showed benefit in patients with resected EGFR-mutated non-small cell lung cancer (NSCLC) in the phase 3 ARTS trial.

🧬 As a third-generation EGFR TKI, aumolertinib targets exon 19 grading deletion and exon 21 L858R mutations, addressing the high post-surgery recurrence risk in stage II–IIIB disease.

🔗 Read more: bit.ly/ONCOnews14J-01

13/01/2026

🤔Missed this episode?

Dr. Shreyas Kalantri shares key insights on quality of life, global oncology, and the future of cancer care in our latest Oncology Spotlight episode.

🎧 Watch here 👉 https://youtu.be/-bH1jc3Nzqo

👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, treatment protocols, and calculators! 🔬In this episode, Dr. Shreyas Kal...

12/01/2026

🚨New Phase III Trial update!

📈 In the phase 3 COMMIT study, FOLFOX + bevacizumab + atezolizumab improved progression free survival (PFS) to 24.5 months vs 5.3 months with atezolizumab alone in dMMR/MSI-H metastatic colorectal cancer (mCRC).

💊 The combination also achieved a higher overall response rate (86.1% vs 46.0%), though adverse events were more frequent and severe.

🔗 Read more: bit.ly/ONCOnews12J-07

12/01/2026

🚨Breaking GI Update!

✅ Preoperative diffusion-weighted magnetic resonance imaging (MRI) reduced futile surgeries in colorectal peritoneal metastases from 42.5% to 26.8% in the DISCO trial.

⚖️ This imaging approach can help better select patients for cytoreductive surgery, minimizing unnecessary procedures and associated risks.

🔗 Read more: bit.ly/ONCOnews12J-06

12/01/2026

🚨Breaking GI Update!

✅ Walking and regular physical activity after treatment can reduce cancer-related fatigue in colorectal cancer survivors.

⏳Activity at diagnosis does not predict long-term fatigue, highlighting the post-treatment recovery period as a key window for intervention.

🔗 Read more: bit.ly/ONCOnews12J-05

12/01/2026

📝This week’s ONCO-IQ Quiz challenge focuses on Gastric Carcinoma. Drop your answers in the comments 👇🏻

Participate in the full quiz here: https://bit.ly/GC-ONCO-IQ-FB

Explore gastric carcinoma and other oncology quizzes across multiple indications, now live on ONCOassist.

12/01/2026

🚨Breaking GI Update!

🧬 Early studies in KRAS(G12D)-mutant pancreatic ductal adenocarcinoma (PDAC) show promising antitumor activity with targeted agents including INCB161734 and setidegrasib, with manageable safety profiles.

🔄 Responses were observed both alone and with chemotherapy, including mFOLFIRINOX (modified leucovorin, fluorouracil, irinotecan, and oxaliplatin).

🔗 Read more: bit.ly/ONCOnews12J-04

12/01/2026

🚨New update!

📊 S1826 Trial (3-year follow-up): Nivolumab-AVD (Doxorubicin, Vinblastine, and Dacarbazine) achieved high 3-year Progression Free Survival (PFS) in adolescents with advanced-stage classic Hodgkin lymphoma, with minimal use of radiotherapy.

✅ The trial highlights how harmonized trial designs can accelerate access to novel therapies for adolescent patients.

🔗 Read more: bit.ly/ONCOnews12J-03

12/01/2026

🚨New Phase III Trial update!

🔔 SCOT Phase III: Three months of adjuvant oxaliplatin–fluoropyrimidine was noninferior to six months, with identical 5-year overall survival (82.4%) in colorectal cancer (CRC).

👉 Clinical impact: A shorter duration reduces cumulative toxicity and should be considered for most patients, with noninferiority demonstrated for capecitabine–oxaliplatin (CAPOX).

🔗 Read more: bit.ly/ONCOnews12J-02